Brad Kahl MDProfessor of Medicine, Washington University School of Medicine; Director, Lymphoma Program, Washington University, St. Louis, MO
Brad Kahl, MD, is a professor of medicine and director of the lymphoma program at Washington University School of Medicine, St. Louis. He earned his medical degree from Tufts University School of Medicine, Boston. He then completed a residency in internal medicine, a year as chief resident, and a fellowship in hematology at the University of Wisconsin.
Dr. Kahl’s research focuses on improving outcomes for patients with lymphoma through testing novel agents and regimens in well-designed clinical trials. He is Chair of the ECOG-ACRIN lymphoma committee since 2009 where he has facilitated the development of multiple large clinical trials. Dr. Kahl is a member of several professional societies, including the American Society of Hematology, American Society of Clinical Oncology, ECOG-ACRIN, and the National Cancer Institute Lymphoma Steering Committee and the Lymphoma Research Foundation Scientific Advisory Board.
DisclosuresDr. Kahl reports the following disclosures:
Commercial Interests - Consultant
Astrazeneca, ADCT Therapeutics, Roche, Genetech, Abbvie, MEI, AcertaPharma, Pharmacyclics, Celgene, Beigene, Kite, Morphosys, Karopharm, Janssen, TG Therapeutics
Genetech - Various Agents, Abbvie - Venetoclax, Celgene/BMS - Liso-Cel, BeiGene-Zanubrutinib, Genmab-Epcoritamab, MEI - Zandelisib, TG Therapeutics - Umbralisib